837364-57-5

Basic information

• Product Name: AG-024322
• Synonyms: AG-024322;5-[3-(5,7-difluoro-1H-benzimidazol-2-yl)-1H-indazol-5-yl]-N-ethyl-4-methyl-3-Pyridinemethanamine;N-((5-((19E)-3-(4,6-DIFLUORO-2H-BENZO[D]IMIDAZOL-2-YLIDENE)-2,3-DIHYDRO-1H-INDAZOL-5-YL)-4-METHYLPYRIDIN-3-YL)METHYL)ETHANAMINE
• CAS NO: 837364-57-5
• Molecular Formula: C23H20F2N6
• Molecular Weight: 418.4419064
• Mol File: 837364-57-5.mol

Chemical Properties

• Boiling Point: 668.4±65.0 °C(Predicted)
• Appearance: /
• Density: 1.361±0.06 g/cm3(Predicted)
• PKA: 7.84±0.30(Predicted)
• CAS DataBase Reference: AG-024322(CAS DataBase Reference)
• NIST Chemistry Reference: AG-024322(837364-57-5)
• EPA Substance Registry System: AG-024322(837364-57-5)

Safety Data

• Hazardous Substances Data: 837364-57-5(Hazardous Substances Data)

Usage

Uses

Used in Oncology:
AG-024322 is used as an anticancer agent for its ability to inhibit the growth of a broad spectrum of cancer cell lines. It targets CDK 1 and 2, key regulators of the cell cycle, thereby disrupting the proliferation of cancer cells and inducing cell cycle arrest and apoptosis.
Used in Drug Resistance Overcoming:
In the context of cancer treatment, AG-024322 is used to address drug resistance, as it has shown efficacy against cancer cells that are resistant to conventional chemotherapy. This property is crucial for improving treatment outcomes in cases where standard therapies have failed.
Used in Preclinical Cancer Models:
AG-024322 is utilized in preclinical models of human cancers to evaluate its potential as a novel anticancer agent. These models are essential for understanding the compound's mechanisms of action and its effectiveness against different types of cancer before it can be considered for clinical trials and eventual use in patients.
Further research is necessary to explore the full potential applications and any limitations of AG-024322 in cancer treatment, ensuring its safety and efficacy for future therapeutic use.

Upstream product

• 837364-62-2 {5-[3-(4,6-difluoro-1H-benzoimidazol-2-yl)-1-(tetrahydro-pyran-2-yl)-1H-indazol-5-yl]-4-methyl-pyridin-3-ylmethyl}-ethyl-carbamic acid tert-butyl ester 

Relevant articles and documents

POLYMORPHS OF {5-[3-(4,6-DIFLUORO-1H-BENZOIMIDAZOL-2-YL)-1H-INDAZOL-5-YL]-4-METHYL-PYRIDIN-3-YLMETHYL}-ETHYL-AMINE

The present invention relates to novel polymorphic forms of of 3{5-[3-(4,6-Difluoro-1 H-benzoimidazol-2-yl)-1H-indazol-5-yl]-4-methyl-pyridin-3-ylmethyl}-ethyl-amine, and to processes for their preparation. Such polymorphic forms may be a component of a pharmaceutical composition and may be used to treat a hyperproliferative disorder or a mammalian disease condition mediated by protein kinase activity.

PHARMACEUTICAL COMPOSITIONS COMPRISING A CDK INHIBITOR

The present invention features pharmaceutical and lyophilized compositions comprising {5-[3-(4,6-Difluoro-1 H-benzoimidazol-2-yl)-1 Hindazol-5-yl]-4-methyl-pyridin-3-ylmethyl}-ethyl-amine, an inhibitor of cyclin-dependent kinases (CDKs). The pharmaceutical and lyophilized compositions are suitable for parenteral administration, wherein the composition comprises {5-[3-(4,6-Difluoro-1 H benzoimidazol-2-yl)-1 H-indazol-5-yl]-4-methyl-pyridin-3-ylmethyl}-ethyl-amine, a Solubilizing Agent, and a Stabilizing Agent as defined herein. Also disclosed are methods of making the compositions, and methods of treating cell-proliferative disorders by administration of the compositions.

SYNTHESIS OF 5-BROMO-4-METHYL-PYRIDIN-3-YLMETHYL)-ETHYL-CARBAMIC ACID TERT-BUTYL ESTER

The present invention relates to novel synthetic methods for the preparation of intermediates of 3{5-[3-(4,6-Difluoro-1H-benzoimidazol-2-yl)-1H-indazol-5-yl]-4-methyl-pyridin-3-ylmethyl}-ethyl-amine.

3,5 DISUBSTITUTED INDAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR MEDIATING OR INHIBITING CELL PROLIFERATION

3,5 disubstituted indazole compounds that modulate and/or inhibit cell proliferation, such as the activity of protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating CDK dependent diseases to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.